Protalix BioTherapeutics, Inc (PLX) Fair Value & Analysis
Healthcare · US · Market cap $179M
Protalix BioTherapeutics, Inc
PLX · US
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price +11.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.27 – $2.91 · fair‑value band $2.02 – $3.37 · the $2.17 price screens below the $2.69 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Protalix BioTherapeutics, Inc (PLX) currently trades at $2.17, while our model-based Fair Value estimate is $2.69 — implying the stock looks roughly 24.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Protalix BioTherapeutics, Inc generated revenue of $76.4M at a net margin of 20.1%. Revenue grew 233.7% year over year. It earns a return on equity of 27.3%. The balance sheet holds a net cash position of $6.4M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Protalix BioTherapeutics, Inc reported revenue of $52.7M in FY2025 versus $38.4M in FY2021, a compound +8.3%/yr. Reported net income was −$6.6M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Protalix BioTherapeutics, Inc (PLX) undervalued?
What is the fair value of PLX?
What is the quality score of PLX?
What is the revenue of Protalix BioTherapeutics, Inc (PLX)?
What is the net profit margin of PLX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.